Dapagliflozin is Well Tolerated in Hospitalized COVID-19 Patients ...Middle East

PR Newswire - News
Dapagliflozin is Well Tolerated in Hospitalized COVID-19 Patients
WASHINGTON, June 27, 2021 /PRNewswire/ -- DARE-19 is the first large randomized clinical trial to assess sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with and without type 2 diabetes hospitalized with COVID-19. Additional findings from the trial were presented today at...

Hence then, the article about dapagliflozin is well tolerated in hospitalized covid 19 patients was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Dapagliflozin is Well Tolerated in Hospitalized COVID-19 Patients )

Apple Storegoogle play

Last updated :

Also on site :